Aspen Technology to Present at the KeyBanc Emerging Technology Summit
Get Alerts AZPN Hot Sheet
Join SI Premium – FREE
BEDFORD, Mass.--(BUSINESS WIRE)-- Aspen Technology, Inc. (NASDAQ: AZPN), a global leader in industrial software, today announced that Antonio Pietri, President and Chief Executive Officer, will present at the KeyBanc Emerging Technology Summit in San Francisco, CA.
The presentation is scheduled for Wednesday, March 6, 2024, at 2:00 p.m. ET (11:00 a.m. PT). The presentation will be webcast live and available for a limited time on the Webcasts and Events section of the company’s Investor Relations website at https://ir.aspentech.com/events-presentations/webcasts-and-events.
About AspenTech
Aspen Technology, Inc. (NASDAQ: AZPN) is a global software leader helping industries at the forefront of the world’s dual challenge meet the increasing demand for resources from a rapidly growing population in a profitable and sustainable manner. AspenTech solutions address complex environments where it is critical to optimize the asset design, operation and maintenance lifecycle. Through our unique combination of deep domain expertise and innovation, customers in asset-intensive industries can run their assets safer, greener, longer and faster to improve their operational excellence. To learn more, visit AspenTech.com.
© 2024 Aspen Technology, Inc., AspenTech, and the Aspen leaf logo are trademarks of Aspen Technology, Inc. All rights reserved.
Source: Aspen Technology, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228729745/en/
Media Contact
Len Dieterle
AspenTech
+1 781-221-4291
[email protected]
Investor Contact
Brian Denyeau
ICR
+1 646-277-1251
[email protected]
Source: Aspen Technology, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- INFRONEER Teams with Accenture to Build New Financial Data and Insights Platform to Advance its Group Management Capabilities in Just Three Months
- “Good Governance Builds Good Companies”: Governance Awareness Campaign Launched by Oasis Across Japan During AGM Season
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
KeyBancSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share